The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study

Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality among neutropenic patients undergoing chemotherapy for acute myeloid leukemia (AML) and stem cell transplantation. The aim of this study was to evaluate the real-life impact of posaconazole prophylaxis. Eighty-four...

Full description

Saved in:
Bibliographic Details
Published in:Turkish journal of haematology 2018, Vol.35 (4), p.277-282
Main Authors: Özkocaman, Vildan, Özkalemkaş, Fahir, Seyhan, Serdar, Ener, Beyza, Ursavaş, Ahmet, Ersal, Tuba, Kazak, Esra, Demirdöğen, Ezgi, Mıstık, Reşit, Akalın, Halis
Format: Article
Language:English
Subjects:
acute myeloid leukemia
Administration, Oral
Adult
Aged
Antifungal agents
Antifungal Agents - administration & dosage
Antifungal Agents - therapeutic use
antifungal prophylaxis
Chemotherapy
Fungal infections
Hematology
Humans
invasive fungal infections
Leukemia
Leukemia, Myeloid, Acute - drug therapy
Male
Middle Aged
Mortality
Neutropenia
Original Research
Patients
posaconazole
Retrospective Studies
Stem cells
Tıp
Transplants & implants
Triazoles - administration & dosage
Triazoles - therapeutic use
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Invasive fungal infections (IFIs) are a significant cause of morbidity and mortality among neutropenic patients undergoing chemotherapy for acute myeloid leukemia (AML) and stem cell transplantation. The aim of this study was to evaluate the real-life impact of posaconazole prophylaxis. Eighty-four adult patients were included with AML under remission induction chemotherapy and posaconazole prophylaxis. The 34 patients in the control group did not receive primary antifungal prophylaxis. The period between June 2006 and January 2009, when antifungal prophylaxis was not administered (control group), was retrospectively compared to the period between December 2010 and May 2012 when primary oral posaconazole prophylaxis was administered in similar conditions (posaconazole group) according to the use of antifungal agents for treatment, breakthrough infections, galactomannan performance, and the necessity for performing bronchoalveolar lavage (BAL) procedures. The two groups were compared according to the use of antifungal agents; progression to a different antifungal agent was found in 34/34 patients (100%) in the control group and in 9/84 patients (11%) in the posaconazole group (p
ISSN:1300-7777
1308-5263
DOI:10.4274/tjh.2017.0430